Table 3.

Association between predisposing factors and ADRs.

Characteristics	N-ADR	ADR*	PR 95% IC Unadjusted	P value	PR 95% IC Adjusted	P value
Patients n (%)	153	115
Age
19–59	81	70	1.00	–	1.00	–
60 or more	72	45	0.81 (0.56–1.19)	0.277	0.82 (0.55–1.21)	0.323
Diagnostic (%)
Rheumatoid arthritis only	105	91	1.00	–	1.00	–
Psoriatic arthritis only	41	22	0.52 (0.23–1.19)	0.123	0.66 (0.28–1.55)	0.342
RA+PsA	7	2	0.89 (0.55–1.41)	0.609	1.07 (0.64–1.78)	0.790
Comorbidity
None	72	58	1.00	–	1.00	–
1 or more	81	57	0.99 (0.69–1.42)	0.946	0.94 (0.64–1.38)	0.735
Patient was guided about risk of medication
No	135	95	1.00	–	1.00	–
Yes	18	20	0.79 (0.49–1.27)	0.325	0.81 (0.49–1.32)	0.393
Health insurance
Private	31	25	1.00	–	1.00	–
Public	122	90	0.95 (0.61–1.48)	0.824	0.91 (0.58–1.43)	0.694
Biologic agent
adalimumab	63	64	1.00	–	1.00	–
abatacept	7	3	0.60 (0.19–1.90)	0.380	0.52 (0.16–1.68)	0.277
efalizumab	7	2	0.44 (0.11–1.80)	0.254	0.57 (0.13–2.46)	0.454
etanercept	29	23	0.88 (0.55–1.41)	0.592	0.86 (0.53–1.40)	0.531
infliximab	27	15	0.71 (0.40–1.24)	0.230	0.73 (0.40–1.31)	0.286
rituximab	18	7	0.56 (0.26–1.21)	0.140	0.42 (0.18–0.96)	0.044
tocilizumab	2	1	0.66 (0.09–4.77)	0.682	0.56 (0.08–4.05)	0.565
Concomitant use of drugs with biologic agents**
No	50	31	1.00	–	1.00	–
Yes	103	84	1.17 (0.78–1.77)	0.446	1.15 (0.75–1.76)	0.534
Concomitant use of DMARDs
No	74	50	1.00	–	1.00	–
Yes	79	65	1.02 (0.61–1.70)	0.935	0.98 (0.58–1.67)	0.944
Duration use of biologic agents (months)
6 to 12 months	24	16	1.00	–	1.00	–
13 months or more	129	99	1.08 (0.64–1.83)	0.777	0.95 (0.55–1.62)	0.839

*ADR ranked as definite or probable.

Adjusted to: age, comorbidity and concomitant use of others drugs.

**DMARDs not included.